Dashboard
Manage Tickers

JNJ JOHNSON & JOHNSON

NYSE jnj.com


$ 192.12 $ 0.95 (0.5 %)    

Thursday, 16-Oct-2025 19:41:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 192.12
$ 191.11
$ 191.66 x 3
$ 192.30 x 1
$ 190.43 - $ 193.05
$ 137.37 - $ 194.40
10,611,760
na
462.69B
$ 0.33
$ 20.42
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2025 06-29-2025 10-Q
2 04-23-2025 03-30-2025 10-Q
3 02-13-2025 12-29-2024 10-K
4 10-23-2024 09-29-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-16-2024 12-31-2023 10-K
8 10-27-2023 10-01-2023 10-Q
9 10-27-2023 10-01-2023 10-Q
10 07-31-2023 07-02-2023 10-Q
11 04-28-2023 04-02-2023 10-Q
12 02-16-2023 01-01-2023 10-K
13 10-27-2022 10-02-2022 10-Q
14 07-29-2022 07-03-2022 10-Q
15 04-29-2022 04-03-2022 10-Q
16 02-17-2022 01-02-2022 10-K
17 10-29-2021 10-03-2021 10-Q
18 07-29-2021 07-04-2021 10-Q
19 04-30-2021 04-04-2021 10-Q
20 02-22-2021 01-03-2021 10-K
21 10-23-2020 09-27-2020 10-Q
22 07-24-2020 06-28-2020 10-Q
23 04-29-2020 03-29-2020 10-Q
24 02-18-2020 12-29-2019 10-K
25 10-28-2019 09-29-2019 10-Q
26 07-29-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-20-2019 12-30-2018 10-K
29 10-31-2018 09-30-2018 10-Q
30 08-02-2018 07-01-2018 10-Q
31 05-01-2018 04-01-2018 10-Q
32 02-21-2018 12-31-2017 10-K
33 11-02-2017 10-01-2017 10-Q
34 08-03-2017 07-02-2017 10-Q
35 05-08-2017 04-02-2017 10-Q
36 02-27-2017 01-01-2017 10-K
37 11-04-2016 10-02-2016 10-Q
38 08-04-2016 07-03-2016 10-Q
39 05-10-2016 04-03-2016 10-Q
40 02-24-2016 01-03-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-reports-strong-phase-3-results-for-multiple-myeloma-therapy
Johnson & Johnson Reports Strong Phase 3 R...
10/16/2025 17:37:03

Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson...

Core News & Articles
Reported Earlier: 'J&J Faces First UK Laws...
10/16/2025 15:25:41

https://www.reuters.com/sustainability/boards-policy-regulation/jj-faces-first-uk-lawsuits-alleging-its-baby-powder-caused-canc...

johnson--johnson-kenvue-named-in-first-ever-uk-legal-action-over-talc-cancer-claims
Johnson & Johnson, Kenvue Named In First E...
10/16/2025 14:18:35

Johnson & Johnson faces 3,000 UK lawsuits alleging asbestos-contaminated talcum powder caused cancer and concealed risks fo...

johnson--johnson-reportedly-faces-major-uk-lawsuit-over-baby-powder-cancer-risks
Johnson & Johnson Reportedly Faces Major U...
10/16/2025 13:09:59

A legal claim involving 3,000 people has been reportedly filed against Johnson & Johnson (NYSE: JNJ) in the U.K., alleging ...

johnson--johnsons-phase-3-majestec-3-trial-becomes-first-to-show-statistically-significant-progression-free-and-overall-survival-benefit-for-investigational-tecvayli--darzalex-faspro-combo-in-relapsedrefractory-multiple-myeloma-as-early-as-second-line-idmc-recommended-unblinding-the-study-based-on-statistically-significant-results
Johnson & Johnson's Phase 3 MajesTEC-3 Tri...
10/16/2025 12:14:17

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multipl...

scott-bessent-says-us-investment-boom-sustainable-under-trump-the-only-thing-slowing-us-down
Scott Bessent Says US Investment Boom 'Sus...
10/16/2025 12:05:56

U.S. Treasury Secretary Scott Bessent credited the country's investment boom to President Donald Trump's policies on We...

these-analysts-boost-their-forecasts-on-johnson--johnson-after-upbeat-q3-earnings
These Analysts Boost Their Forecasts On Jo...
10/15/2025 18:04:28

johnson--johnson-rules-out-big-acquisitions-reiterates-focus-on-small-deals-analyst
Johnson & Johnson Rules Out Big Acquisitio...
10/15/2025 17:56:28

Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing...

Core News & Articles
New Jersey Rep. Thomas Kean Sold Up to $21...
10/15/2025 15:00:15

citigroup-maintains-buy-on-johnson--johnson-raises-price-target-to-215
Citigroup Maintains Buy on Johnson & Johns...
10/15/2025 14:56:52

Citigroup analyst Joanne Wuensch maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $213...

stifel-maintains-hold-on-johnson--johnson-raises-price-target-to-190
Stifel Maintains Hold on Johnson & Johnson...
10/15/2025 14:40:58

Stifel analyst Rick Wise maintains Johnson & Johnson (NYSE:JNJ) with a Hold and raises the price target from $165 to $190.

raymond-james-maintains-outperform-on-johnson--johnson-raises-price-target-to-209
Raymond James Maintains Outperform on John...
10/15/2025 14:20:47

Raymond James analyst Jayson Bedford maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price targe...

morgan-stanley-maintains-equal-weight-on-johnson--johnson-raises-price-target-to-190
Morgan Stanley Maintains Equal-Weight on J...
10/15/2025 13:08:30

Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price tar...

b-of-a-securities-maintains-neutral-on-johnson--johnson-raises-price-target-to-204
B of A Securities Maintains Neutral on Joh...
10/15/2025 12:26:27

B of A Securities analyst Tim Anderson maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target...

looking-at-johnson--johnsons-recent-unusual-options-activity
Looking At Johnson & Johnson's Recent Unus...
10/14/2025 19:01:48

ubs-maintains-buy-on-johnson--johnson-raises-price-target-to-214
UBS Maintains Buy on Johnson & Johnson, Ra...
10/14/2025 16:06:49

UBS analyst Danielle Antalffy maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $190 to...

johnson--johnson-cfo-joseph-wolk-says-2026-adj-eps-expected-to-exceed-current-street-estimates-by-as-much-as-5-cents
Johnson & Johnson CFO Joseph Wolk Says 202...
10/14/2025 13:14:19

- Conf Call

johnson--johnson-cfo-joseph-wolk-says-expect-rulings-on-certain-legal-motions-pending-in-talc-litigation-by-q1-2026-says-2026-revenue-growth-in-total-expected-to-exceed-5-above-current-street-estimates
Johnson & Johnson CFO Joseph Wolk Says Exp...
10/14/2025 13:12:09

- Conf Call

johnson--johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook
Johnson & Johnson To Separate Orthopedics ...
10/14/2025 12:51:28

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthoped...

stock-market-today-dow-jones-nasdaq-futures-tumble-ahead-of-big-bank-earningsgoldman-sachs-jpmorgan-citigroup-in-focus-updated
Stock Market Today: Dow Jones, Nasdaq Futu...
10/14/2025 12:24:14

Editor’s Note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the sto...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION